NanoLogix Rapid TB Detection Results Published In Journal of Microbial & Biochemical Technology

NanoLogix Rapid TB Detection Results Published In Journal of Microbial & Biochemical Technology

Major Third-party R&D lab achieves 5-day Tuberculosis detection, compared to weeks for standard tests

HUBBARD, Ohio--(BUSINESS WIRE)-- NanoLogix (OTC Markets: NNLX)


An independent third-party study by one of the foremost Biomedical Research centers in the U.S. has demonstrated that NanoLogix's BioNanoPore (BNP) Ultra-Fast Identification Technology enables detection of live Tuberculosis cultures in five days as opposed to two+ weeks with traditional methods.

The peer reviewed study appears in the online edition of the Journal of Microbial & Biochemical Technology.

http://www.omicsonline.org/1948-5948/pdfdownload.php?download=JMBT-04-147.pdf&&aid=10157

The authors conclude: "Ideally, highly accurate diagnostic tests for TB would be simple to perform, not require specialized equipment or facilities, provide rapid results for decreased time to treatment, are readily available, and cost-effective for the end user. These qualities are especially important in developing or high-TB burdened countries where the access and ability to purchase specialized equipment is limited, and number of trained personnel is low. The results of the present study demonstrate a proof-of-principal for BNP™ Middlebrook in detecting TB compared to the Middlebrook 7H10 reference test and should be considered as an ideal candidate for future evaluation of clinical samples."

Current rapid detection methods using PCR (molecular diagnostic) technology have a number of limitations in the fight against TB. They are unable to differentiate between live actual infection, and presence of dead bacteria in immune patients. Furthermore, PCR technology is very expensive, and needs specially trained personnel to perform testing, something not available, or even feasible, in the areas of the world most in need. Furthermore, even with PCR, the standard still requires culture positivity, which currently is a 3-4 week process. In addition, drug sensitivity is equally as important as identification, and early results using our BNF technology are extremely encouraging, taking only a few hours after bacterial identification.

Potential for the use of BNP technology is vast, said Bret T. Barnhizer, CEO of NanoLogix. "In addition to BNP's use in detecting many other bacteria, we see this technology as potentially providing both a standalone method for determining the presence of an actual TB infection and also a complementary method that can be used with either our BioNanoFilter (BNF) technology or molecular diagnostics methods for initial TB screening. We hope that our BNP rapid culture results will make it possible to finally monitor antibiotic treatment for TB in a close-to-real-time manner that is currently unavailable to practitioners. This ability could provide major assistance in the ongoing campaign to combat the scourge of Tuberculosis. We are committed to helping wipe out this horrible disease that takes over one million lives a year. As a partner in the Stop TB Alliance, we look forward to working further with them and WHO officials in a real effort to eradicate TB."

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit: www.nanologix.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

anImage


Investors:
NanoLogix, Inc.
Carol Surrena, 330-534-0800
carol@nanologix.com

KEYWORDS:   United States  North America  Ohio

INDUSTRY KEYWORDS:

The article NanoLogix Rapid TB Detection Results Published In Journal of Microbial & Biochemical Technology originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Professional Vs Do it Yourself Investing

Should you get advice or DYI?

View Course »

Introduction to Value Investing

Are you the next Warren Buffett?

View Course »

Add a Comment

*0 / 3000 Character Maximum